Literature DB >> 24496191

Cardiorenal syndrome type 4: management.

Anna Clementi1, Grazia Maria Virzì, Alessandra Brocca, Massimo de Cal, Giorgio Vescovo, Antonio Granata, Claudio Ronco.   

Abstract

Cardiorenal syndrome (CRS) type 4, or chronic renocardiac syndrome, has been defined as 'chronic abnormalities in renal function leading to cardiac disease' and recognizes the extreme burden of cardiovascular (CV) disease (CVD) risk in patients with chronic kidney disease (CKD). CKD is common and increasingly recognized as a risk factor for CVD. Although during the past 10 years CV morbidity and mortality have decreased markedly in the general population, their rates still remain high among CKD patients. For this reason, CKD patients should be evaluated thoroughly for CV risk factors which require an aggressive management, given the significant implications of CRS type 4 at both individual and societal level. We will review the management of the most important conventional and nonconventional CVD risk factors related to CKD.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 24496191     DOI: 10.1159/000356369

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  6 in total

Review 1.  Cellular apoptosis in the cardiorenal axis.

Authors:  Grazia Maria Virzì; Anna Clementi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2016-03       Impact factor: 4.214

2.  Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4.

Authors:  Rasha M S M Mohamed; Shimaa M Elshazly; Ola E Nafea; Dalia M Abd El Motteleb
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-08-16       Impact factor: 3.000

3.  Apocynin Attenuates Cardiac Injury in Type 4 Cardiorenal Syndrome via Suppressing Cardiac Fibroblast Growth Factor-2 With Oxidative Stress Inhibition.

Authors:  Yang Liu; Yu Liu; Xun Liu; Jie Chen; Kun Zhang; Feifei Huang; Jing-Feng Wang; Wanchun Tang; Hui Huang
Journal:  J Am Heart Assoc       Date:  2015-06-24       Impact factor: 5.501

Review 4.  Cardiorenal Protection in Diabetic Kidney Disease.

Authors:  Jason F Lee; Ecaterina Berzan; Vikas S Sridhar; Ayodele Odutayo; David Z I Cherney
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-19

Review 5.  Kidney Replacement Therapy in Cardiorenal Syndromes.

Authors:  Daniel Patschan; Kim Drubel; Igor Matyukhin; Benedikt Marahrens; Susann Patschan; Oliver Ritter
Journal:  J Clin Med Res       Date:  2022-07-29

6.  Ultrasonic evaluation of renal cortex arterial area enables differentiation between hypertensive and glomerulonephritis-related chronic kidney disease.

Authors:  Arkadiusz Lubas; Grzegorz Kade; Robert Ryczek; Piotr Banasiak; Przemysław Dyrla; Katarzyna Szamotulska; Daniel Schneditz; Stanisław Niemczyk
Journal:  Int Urol Nephrol       Date:  2017-06-01       Impact factor: 2.370

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.